{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:25:23Z","timestamp":1794029123867,"version":"4.8.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtct.2026.10.037","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:17:23Z","timestamp":1792797443000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk Factors for Admission to the Intensive Care Unit and Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Acute Myeloid Leukemia"],"prefix":"10.1016","author":[{"given":"Corentin","family":"Orvain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna B.","family":"Halpern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Basom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda M.","family":"Sandmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.10.037_bib0001","doi-asserted-by":"crossref","unstructured":"McDonald GB, Sandmaier BM, Mielcarek M, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003\u20132007 versus 2013\u20132017 cohorts. Ann Intern Med; 172: 229\u2013239.","DOI":"10.7326\/M19-2936"},{"key":"10.1016\/j.jtct.2026.10.037_bib0002","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/bmt.2013.141","article-title":"Risk factors for ICU admission and ICU survival after allogeneic hematopoietic SCT","volume":"49","author":"Benz","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0003","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/bmt.2015.55","article-title":"Changes in intensive care for allogeneic hematopoietic stem cell transplant recipients","volume":"50","author":"Lenglin\u00e9","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0004","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jcrc.2015.06.020","article-title":"Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen: outcomes of patients admitted to intensive care unit","volume":"30","author":"Mokart","year":"2015","journal-title":"J Crit Care"},{"key":"10.1016\/j.jtct.2026.10.037_bib0005","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/bmt.2015.269","article-title":"A reappraisal of ICU and long-term outcome of allogeneic hematopoietic stem cell transplantation patients and reassessment of prognosis factors: results of a 5-year cohort study (2009\u20132013)","volume":"51","author":"Platon","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0006","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/TP.0000000000001143","article-title":"Different impact of the number of organ failures and graft-versus-host disease on the outcome of allogeneic stem cell transplantation recipients requiring intensive care","volume":"101","author":"Orvain","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.10.037_bib0007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41409-022-01897-y","article-title":"Impact of pre-transplant individual comorbidities on risk of ICU admission and survival outcomes following allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Jamy","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0008","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s00277-023-05612-9","article-title":"Temporal trends in critical care utilization and outcomes in allogeneic hematopoietic stem cell transplant recipients","volume":"103","author":"Heybati","year":"2024","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0009","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00134-018-5347-x","article-title":"Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients","volume":"44","author":"Lueck","year":"2018","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.jtct.2026.10.037_bib0010","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/bmt.2010.255","article-title":"Outcome in critically ill patients with allogeneic BM or peripheral haematopoietic SCT: a single-centre experience","volume":"46","author":"Depuydt","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0011","doi-asserted-by":"crossref","first-page":"865.e1","DOI":"10.1016\/j.jtct.2021.06.026","article-title":"Sequential organ failure assessment score and the need for organ support predict mortality in allogeneic stem cell transplant patients admitted to the intensive care unit","volume":"27","author":"D\u00edaz-Lagares","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.10.037_bib0012","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1164\/rccm.202401-0135OC","article-title":"Outcomes in critically ill allogeneic hematopoietic stem-cell transplantation recipients","volume":"210","author":"Lafarge","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jtct.2026.10.037_bib0013","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56322-0","article-title":"Prognostic factors and outcome of adult allogeneic hematopoietic stem cell transplantation patients admitted to intensive care unit during transplant hospitalization","volume":"9","author":"Michel","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtct.2026.10.037_bib0014","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1200\/JCO.2005.03.9073","article-title":"Outcome of critically ill allogeneic hematopoietic stem-cell transplantation recipients: a reappraisal of indications for organ failure supports","volume":"24","author":"P\u00e8ne","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0015","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41409-020-0857-x","article-title":"Trajectories of acute graft-versus-host disease and mortality in critically ill allogeneic-hematopoietic stem cell recipients: the Allo-GRRR-OH score","volume":"55","author":"Pichereau","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0016","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41409-018-0181-x","article-title":"Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality","volume":"53","author":"Saillard","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0017","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/bjh.12294","article-title":"Improved intensive care unit survival for critically ill allogeneic haematopoietic stem cell transplant recipients following reduced intensity conditioning","volume":"161","author":"Townsend","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3676","article-title":"Trends in late mortality and life expectancy after allogeneic blood or marrow transplantation over 4 decades: a blood or marrow transplant survivor study report","author":"Bhatia","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0019","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41409-022-01909-x","article-title":"Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remission","volume":"58","author":"Walter","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0021","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0022","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0023","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0024","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0025","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1182\/blood.2021014804","article-title":"Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML","volume":"139","author":"Paras","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0026","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092339","article-title":"Conditioning intensity, pre-transplant flow cytometric measurable residual disease, and outcome in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation","volume":"12","author":"Morsink","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.jtct.2026.10.037_bib0027","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0028","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1182\/blood-2013-06-506725","article-title":"Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0029","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.10.037_bib0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1200\/JCO.2015.63.3826","article-title":"Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease\u2013based definition of complete remission?","volume":"34","author":"Araki","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0031","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/leu.2016.46","article-title":"Pre- and post-transplant quantification of measurable (\u2018minimal\u2019) residual disease via multiparameter flow cytometry in adult acute myeloid leukemia","volume":"30","author":"Zhou","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.10.037_bib0032","article-title":"Acute myeloid leukemia minimal residual disease detection: the difference from normal approach","volume":"93","author":"Wood","year":"2020","journal-title":"Curr Protoc Cytom"},{"key":"10.1016\/j.jtct.2026.10.037_bib0033","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.bbmt.2014.09.022","article-title":"Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission","volume":"21","author":"Walter","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0034","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41409-019-0739-2","article-title":"Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia","volume":"55","author":"Hoffmann","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0035","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/s41375-019-0671-x","article-title":"Comparative analysis of total body irradiation (TBI)-based and non-TBI-based myeloablative conditioning for acute myeloid leukemia in remission with or without measurable residual disease","volume":"34","author":"Morsink","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.10.037_bib0036","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/s41375-020-0717-0","article-title":"Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML","volume":"34","author":"Morsink","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2026.10.037_bib0037","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2006-01-0254","article-title":"An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens","volume":"108","author":"Leisenring","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.10.037_bib0038","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.10.037_bib0039","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2012.47.2365","article-title":"Outcomes of critically ill patients with hematologic malignancies: prospective multicenter data from France and Belgium\u2014a Groupe de Recherche Respiratoire en R\u00e9animation Onco-H\u00e9matologique Study","volume":"31","author":"Azoulay","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0040","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.24.00184","article-title":"Post-transplant cyclophosphamide\u2013based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors","author":"Shaffer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.10.037_bib0041","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1200\/JCO.2013.50.5867","article-title":"Hematopoietic cell transplantation\u2013specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit","volume":"31","author":"Bayraktar","year":"2013","journal-title":"J Clin Oncol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600850X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672600850X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T04:54:28Z","timestamp":1794027268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672600850X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S266663672600850X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.037","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk Factors for Admission to the Intensive Care Unit and Mortality in Allogeneic Hematopoietic Cell Transplant Recipients with Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.10.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}